• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pharvaris N.V. (NQ: PHVS )

    16.18 +0.24 (+1.51%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 101,604
    Open 15.89
    Bid (Size) 15.30 (1)
    Ask (Size) 17.07 (1)
    Prev. Close 15.94
    Today's Range 15.52 - 16.41
    52wk Range 15.00 - 33.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
    Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
    Via Investor's Business Daily
    Pharvaris Announces Annual Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire

    Performance

    YTD
    -37.46%
    -37.46%
    1 Month
    -4.82%
    -4.82%
    3 Month
    -28.41%
    -28.41%
    6 Month
    -46.35%
    -46.35%
    1 Year
    -8.64%
    -8.64%

    More News

    Read More
    Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Analyst Expectations for Pharvaris's Future
    Via Benzinga
    Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
    Via InvestorPlace
    Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
    Via InvestorPlace
    Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Announces Extraordinary Meeting of Shareholders
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris to Present at the WSAAI Annual Meeting 2024
    From Pharvaris N.V.
    Via GlobeNewswire
    Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
    Via Investor's Business Daily
    Exposures Product Safety
    FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
    Via Benzinga
    Exposures Product Safety
    Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
    From Pharvaris N.V.
    Via GlobeNewswire
    Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
    From Pharvaris N.V.
    Via GlobeNewswire
    Gold Moves Higher; Campbell Soup Earnings Top Expectations
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks
    Via Benzinga
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.